Development Status

The drugs and devices from our portfolio companies follow a clear development path from discovery to approval.

Current Therapeutics Development Status

Discovery
Pre-Ind
IND
Phase 1
Phase 2
Phase 3
Advanced small molecules
Advanced small molecules
Elraglusib | Actuate Therapeutics
Zervimesine | Cognition Therapeutics
ONL1204 | ONL Therapeutics
LTI-03 | Rein Therapeutics
RBT-1 | Renibus Therapeutics
AI Drug Development
AI Drug Development
LP-300 | Lantern Pharma
LP-184 | Lantern Pharma
LP-284 | Lantern Pharma
Engineered Cell Therapy
Engineered Cell Therapy
ISP-001 | Immusoft
ISP-002 | Immusoft
INAB-100 | IN8bio
Macrophage Immunotherapy
Macrophage Immunotherapy
RB-1355 | BobcatBio
Recombinant proteins / antibodies

Recombinant proteins / antibodies

rhPDVLG3 | Stream Biomedical
TTHX1114 | Trefoil Therapeutics
Gene Therapy
Gene Therapy
OPGx-LCA5 | Opus Genetics
OPGx-BEST1 | Opus Genetics
Medical Devices
Medical Devices
i-Lumen AMD | i-Lumen Scientific
Top